Expression of MET is elevated in basal‐like tumors and inflammatory breast carcinoma (Garcia et al., 2007; Ponzo and Park, 2010); however, it is still not fully understood how MET is regulated in breast cancer cells. Here, MET is linked to breast carcinoma.